Cryptococcus spp., Identification and Susceptibility to Antifungals in Isolated in Laboratory of Reference in The State of Rio Grande Do Sul, Brazil


Department of Analysis, Faculty of Pharmacy, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Received: 10 Jan 2020 / Accepted: 20 March 2020 / Published online: 01 April 2020

*Corresponding Author Email: mezzari@ufrgs.br

Abstract
Introduction: The Cryptococcus spp., fungus with opportunistic behavior, present in environmental sources, bird excreta, remains of trees, among others. It is inhaled by the individual, causing infection that can spread to other organs and systems with tropism through the central nervous system, causing meningoencephalitis. It is estimated that C. neoformans causes more than one million new cases of cryptococcosis per year, about 625,000 deaths. Meningoencephalitis, the most common clinical manifestation, is estimated to cause 120,000 to 240,000 deaths per year worldwide.

Methods: This study was conducted from January 2012 to June 2019. Biological materials were processed, mainly the cerebrospinal fluid of patients with suspected cryptococcosis. All the phenotypically identified isolates were confirmed by the Polymerase Chain Reaction (PCR) molecular technique. The antifungals flucnazole, itraconazole and amphotericin B were also tested to verify the sensitivity profile of the isolates.

Conclusions and discussion: In this study it was possible to observe and confirm a higher prevalence of Cryptococcus neoformans species than C. gattii. Azole resistance was also observed by the fungus Cryptococcus spp., suggesting a possible synergism of azoles with anti-inflammatory substances, but further studies are needed both in vitro and in vivo. The imminent biological risk from the presence of the two fungal species in the environment, including the confirmation of antifungal resistant strains, corroborate the need for continuous environmental monitoring, including the presence of new pathogenic species and consequently how to conduct treatment in the various clinic presentations by this yeast.

Keywords

*****
INTRODUCTION:
Cryptococcosis is a fungal infection caused by the yeast of the genus Cryptococcus, whose most frequent species are C. neoformans and C. gattii (7). They are responsible for systemic infections that especially affect immunosuppressed individuals, such as newborns, transplanted individuals and those with acquired immunodeficiency syndrome (AIDS) (8). As an etiological agent, it is estimated that C. neoformans causes more than one million new cases of cryptococcosis per year, with about 625,000 deaths (6). Cryptococcus spp. is a fungus with opportunistic behavior, has the airway as a gateway causing pulmonary infection and later spreading to other organs and systems, among them the tropism by the central nervous system, causing meningoencephalitis (1, 6, 20).

As for cryptococcal meningitis, the most common clinical manifestation, it is estimated to result in 120,000 to 240,000 deaths per year worldwide (22). This microorganism is found in environmental sources, especially where there is contamination by pigeon excreta and also in substrates such as tree hollows, hornet nests, bat feces, among others (13, 21) and with higher prevalence in tropical and subtropical regions (25).

Worldwide and especially in Latin America, C. neoformans causes more than 90% of cases of cryptococcosis (3), predominantly in patients with human immunodeficiency virus (HIV), whereas C. gattii is more likely to infect immunocompetent individuals (10, 13). Latin America has been identified as the region of the American continent with the highest number of cases per year, with approximately 5,300 cases. Of these, Brazil and Colombia were the countries with the highest incidence, between 1,001 and 2,500 cases of cryptococcosis (4).

In Rio Grande do Sul (RS) reports indicate a higher prevalence in the metropolitan region of Porto Alegre (RS), with males and immunosuppressed individuals being the most affected by the disease, with the main immunosuppression factor being AIDS (6, 16).

The golden standard treatment for cryptococcosis is the combination of amphotericin B and 5-flucytosine (11). However, due to its high cost, 5-flucytosine is not present in therapeutic protocols in several countries, giving rise to azole drugs such as fluconazole and itraconazole (26). However, azoles have been showing ineffectiveness due to the development of resistant strains (9). Moreover, although resistance to amphotericin B polyene is considered rare and has a good activity spectrum, this drug has restricted use due to nephrotoxicity problems (11, 30).

Currently, few antifungals are commercially available and the development of new drugs has not accompanied the development of resistant strains (12). Combination therapy with two or more antifungals has been tested in an attempt to reduce antifungal resistance and decrease the toxicity of each drug, but its side effects should still be carefully evaluated (10, 29). Therefore, studies of in vitro association with non-antifungal agents and antifungal drugs have been suggested but it is still necessary to delineate in vitro assays and consequently clinical trials (10, 29).

The present study aimed to verify the presence of Cryptococcus spp. species isolated in a reference laboratory of the State of Rio Grande do Sul (LACEN-RS), as well as to evaluate the susceptibility profile to antifungals. The research project was approved by the research ethics committee under number 29595.

METHODOLOGY:
The data obtained in this study come from the Mycology section of the Central Laboratory of the State of Rio Grande do Sul (LACEN-RS) from January 2012 to June 2019. In LACEN-RS, biological materials were processed, mainly the cerebrospinal fluid of patients with suspected cryptococcosis. The mycology department of LACEN-RS, when receiving the patient’s biological sample, sowed in a culture medium Sabouraud dextrose agar with chloramphenicol without cycloheximide, being incubated at a temperature of 25 to 30ºC, and observed daily for seven days. After the smooth, moist colonies indicative of Cryptococcus spp. were submitted to phenotypic tests of urease which presents pink coloration for Cryptococcus spp. (urease positive) and no change in medium color for Candida spp. (urease negative). In positive cases for Cryptococcus spp. the canavanine and glycine test were used, with a canavanine glycine bromothymol blue (CGB) medium used as confirmation to Cryptococcus gattii and Cryptococcus neoformans species.

C. gattii is glycine resistant and hydrolyses L-canavanine, therefore degradation occurs in ammonia, altering the pH of the medium and changing the color of the culture medium to cobalt blue. C. neoformans is inhibited by glycine and does not hydrolyze L-canavanine, does not alter the pH of the medium and therefore the culture medium does not change color. All the phenotypically identified by LACEN-RS isolates were then sent to the UFRGS Faculty of Pharmacy Mycology Laboratory (Biomicolab) to be confirmed by the Polymerase
Chain Reaction (PCR) molecular technique through the primers CNa-70S (5′-ATTGCGTCCACCAAGGAGCTC-3′) and CNa-70A (5′-ATTGCGTCCATGTTACGTGGC-3′). For susceptibility tests, the antifungals fluconazole (FLC), itraconazole (ITC) and amphotericin B (AMB) were tested. According to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) (2), the FLC stock solution (Metrochem Api Private Limited, India) was prepared in distilled water. ITC (Metrochem Api Private Limited) and AMB (Metrochem Api Private Limited) stock solutions were prepared in DMSO (Nuclear, Brazil). For the experiments, the compounds were diluted in RPMI 1640 medium (Sigma-Aldrich) to obtain a maximum concentration of 2% Dimethyl sulfoxide (DMSO). Minimum inhibitory concentrations (MICs) of antifungal agents were determined in duplicate by the micro dilution in broth method according to protocol M27-A3 (CLSI, 2008). Serial dilutions were made twice in RPMI 1640 medium (Sigma-Aldrich) buffered with MOPS (Sigma-Aldrich) and the concentration ranges tested were: 0.125 - 64 µg/ml FLC, 16 - 0.0312 µg/ml of ITC and 0.0312 - 16 µg/ml AMB. MICs values were defined as the lowest concentration of compounds in which the tested microorganisms showed no visible growth (AMB) or reduced 50% or 90% growth (FLC and ITC) within 72 h.

RESULTS AND DISCUSSION:
The period studied corresponds from January 2012 to June 2019 totalizing 139 isolates of Cryptococcus spp. The total number and confirmed cases per year are described in Figure 1.

Figure 1: Number of Cryptococcus spp. isolates per year, isolated at LACEN- RS in the period of January 2012 to June 2019.

Figure 2: Percentage between the two species of confirmed Cryptococcus spp., C. neoformans and C. gattii.
Figure 3: Total Cryptococcus species isolated and identified during the period, annually.

Figure 4: Percentage difference in the number of cases of Cryptococcus spp. by gender

Figure 5: Annual distribution of Cryptococcus spp. isolates in the cities of the state of Rio Grande do Sul during the period of the study.
Of the 139 confirmed isolates of Cryptococcus spp., 25 isolates of Cryptococcus neoformans were randomly selected to check the susceptibility profile to the fluconazole, itraconazole and amphotericin B antifungals. Results were expressed as susceptibility profile (µg/ml) expressed in ranges of variation of minimum and maximum values of Minimum Inhibitory Concentration (MIC ranges), geometric mean (GM), MIC50 (MIC value that inhibits 50% of the isolates) and MIC90 (MIC value that inhibits 90% of the isolates) for the antifungals fluconazole (FLC), itraconazole (ITC) and amphotericin B (AMB), the results are presented in Table I.

Table I. Susceptibility profile (µg/ml) of twenty-five isolates of Cryptococcus neoformans to antifungal agents expressed in ranges of variation of minimum and maximum MIC values (MIC ranges), geometric mean (GM), MIC50 (MIC value that inhibits 50% of the isolates) and MIC90 (MIC value that inhibits 90% of the isolates).

<table>
<thead>
<tr>
<th>Agents</th>
<th>MIC range (µg/ml)</th>
<th>GM (µg/ml)</th>
<th>MIC50 (µg/ml)</th>
<th>MIC90 (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITC</td>
<td>0.0312 - 16</td>
<td>0.66</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>FLC</td>
<td>0.25 – 8</td>
<td>1.74</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>AMB</td>
<td>0.5 – 16</td>
<td>6.17</td>
<td>4</td>
<td>16</td>
</tr>
</tbody>
</table>

The number of confirmed isolates of Cryptococcus spp. at the Central Laboratory of the State of Rio Grande do Sul (LACEN-RS) from January 2012 to June 2019 were 139 cases from 29 cities of the State of Rio Grande do Sul, with an average of 17.4 (12.5%) cases per year. In 2013, it was the year with the highest number of isolates, 25.0 (17.9%) followed by 2015 with 23.0 (16.5%) cases of isolation and identification of Cryptococcus spp. (Figure 1). These data in relation to the annual isolates agree with the literature when observed by regions or countries (4).

We can observe that it had been a prevalence of Cryptococcus neoformans comparing to Cryptococcus gattii in the total of isolates during the period of study (Figure 2). In the present study 94% of the cases have Cryptococcus neoformans and 6% have Cryptococcus gattii as the etiological agent, corroborating with the literature, with Cryptococcus neoformans causing over 90% of the cryptococcosis cases worldwide (1). In this study, 2013 was the year with the largest number, 24 (17.3%) of Cryptococcus neoformans isolates, with 2017 and 2018 as the ones with the highest number of isolates, 3 (2.2%) of Cryptococcus gattii (Figure 3). This result corroborates with epidemiological studies from other regions of the world (4).

Based on literature findings, including data published in the Brazilian Cryptococcosis Consensus in 2008 (3,4), 78% of confirmed cases of infection are male, as reported by the Ibero American Cryptococcal Study Group in 2003 (17), which refers to the incidence of 5.1 times higher in men than in women. In the present study, 65% of confirmed cases were in male patients (Figure 4). It is possible that female hormones play an important role in the body’s defense against Cryptococcus spp., as previously established in paracoccidioidomycosis. In studies with rats, females infected with Cryptococcus neoformans had higher levels of TNF-α and IFN-γ in the spleen and blood compared to males (6,16,18). Of the 139 isolates of Cryptococcus spp., 56 (40.3%) were predominant in the cities of the metropolitan region of Porto Alegre, where 22 (39.3%) in the city of Novo Hamburgo, 22 (39.3%) in Canoas and 12 (21.4%) in Porto Alegre (Figure 5). Regarding the annual distribution by city of the state of Rio Grande do Sul, the years with the largest number of isolates were 25 (18.0%) in 2013 and 23 (16.5%) in 2015, confirming again that Novo Hamburgo was the city with the largest number of isolates, 8 (5.6%) in 2013, and Canoas had the highest number, 7 (5.0%) in 2015, followed by Porto Alegre with 4 (2.9%), results that can be justified due to being cities of the metropolitan region of Porto Alegre, with a high concentration of pigeons, large urban centers and consequently greater contact of individuals with the infecting elements of the fungus. However, this factor should be better evaluated including factors such as the patient’s occupation and origin that may contribute to the acquisition of the disease. These data corroborate with previous studies realized in the state of Rio Grande do Sul (18,19,25).

Table I shows that isolates with low sensitivity to antifungal agents were found. These fungi in the environment, including areas of high concentration of people, may pose as a biohazard, and the presence of antifungal resistant strains may lead to a different way of treating the pathologies caused by this yeast (20). Fuentefria et al. (2017) (5) describes that the limited efficacy and difficulty of introducing new antifungals in the market should be considered corroborating the recommendation of using drug.
combination as a therapeutic strategy for the treatment of potentially fatal invasive fungal infections. Other studies also reinforce this perspective and by detecting synergism between anti-inflammatory drugs with azoles for both Candida albicans and Cryptococcus neoformans, increasing the susceptibility of isolates to these antifungal agents (21,26), but in the present study such recommendations described by other authors have not been tested, which leads to a future focus on isolation and identification of species of Cryptococcus spp., as well as to monitor the susceptibility profile of these potentially severe and often fatal mycosis agents.

CONCLUSIONS:
From January 2012 to June 2019, it was possible to observe and confirm a higher prevalence of isolates of the species Cryptococcus neoformans, and its higher incidence in men, which corroborates the data already described in the literature. As for the region with the largest number of isolates, the metropolitan region of Porto Alegre stands out, in the cities of Novo Hamburgo, Canoas and Porto Alegre, cities with high population density and the presence of a large number of pigeons. The results of this study confirm that azole resistance already exists for the fungus Cryptococcus spp. when used in cryptococcosis therapy. However, the synergism of azoles with anti-inflammatory substances need further studies both in vitro and in vivo in clinical situations to approve the beneficial effects of this combination.

The imminent biological risk from the presence of these two fungal species present in the environment, including the confirmation of antifungal resistant strains corroborates the need for continuous environmental monitoring, including the presence of new pathogenic species and consequently the way to conduct treatment in the various clinical presentations caused by this year.

REFERENCES:


